(AOF) – Mauna Kea Technologies announces today the initiation of patient recruitment as part of a clinical study aimed at evaluating the ability of its Cellvizio platform to help physicians quickly and precisely position a biopsy tool at the center of peripheral lung nodules. Medtech says the study will combine its needle-and-probe laser confocal endomicroscopy platform with robot-assisted bronchoscopy, via Intuitive Surgical, Inc.’s Ion platform for peripheral lung biopsy navigation and guidance. minimally invasive.
Mauna Kea clarified that the main objective of this study is to evaluate Cellvizio’s ability to improve diagnostic yield and confirmation accuracy of successful lesion targeting (“tool in lesion”) and diagnostic sampling. definitive lesion (“lesion in the tool”) during robotic-assisted bronchoscopy procedures. Secondary objectives are to assess the reproducibility of its use across multiple institutions and to assess its ability to diagnose malignancy versus non-malignancy.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.